Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer: A non-inferiority meta-analysis

Introduction

For patients diagnosed with triple-negative breast cancer (TNBC), the sequential use of anthracyclines and taxanes is the standard adjuvant treatment, when this is indicated. However, anthracycline-related toxicities represent a concern. We conducted a meta-analysis to assess whether anthracycline-free regimens are non-inferior to standard, sequential regimens.

Patients and methods

We used a complex search strategy to query multiple databases. The population included patients who underwent primary surgery for TNBC, eligible for adjuvant chemotherapy and randomised in a phase 2 or 3 clinical trial. We fitted non-inferiority (NI) margins using published treatment effects. We calculated risk ratios (RR) for recurrence or death.

Results

Eight studies out of 3410 potentially eligible records were included in the meta-analysis, for an overall population of 4292 patients. The RR for recurrence was 1.05 (95 % confidence interval (CI) 0.93–1.19), with an upper bound superimposing on the NI margin of 1.19. In a sensitivity analysis excluding the two studies using CMF, the recurrence RR for the comparison between taxane-only chemotherapy and anthracycline-based sequential chemotherapy was RR 0.97 (95 % CI 0.84–1.11). The RR for death was 1.17 (95 % CI 1.00–1.37), with an upper bound crossing the NI margin of 1.16.

Conclusions

Anthracycline-free adjuvant chemotherapy may represent an option for patients with early TNBC who are not eligible for pre-operative treatment and for whom sparing anthracyclines should be considered (e.g., young patients with small tumours, patients at risk of adverse effects). Non-inferiority was more evident for taxane-only chemotherapy than for anthracycline-free regimens at large. However, our results call for caution considering the remarkable heterogeneity in the study patient populations. This meta-analysis should prompt further research into strategies for patient selection, including the use of prognostic biomarkers for risk stratification.